Medivir AB (CHIX:MVIRS) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:MVIRS Medivir AB CHIX:MVIRS
50 GF Score
Price kr2.00
GF Value kr1.24
! 2 Warning Signs
View Full Analysis

What is Medivir AB Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

CHIX:MVIRS
50GF Score
Medivir AB CHIX:MVIRS
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Medivir AB (CHIX:MVIRS) Overvalued in 2026?

Based on GuruFocus' analysis, Medivir AB stock appears to be overvalued. The current stock price of kr2.00 is trading 61% above its estimated GF Value™ of kr1.24.

Key valuation signals for CHIX:MVIRS:

  • Short Ratio:
  • GF Value™: kr1.24 vs. price of kr2.00 (61% above fair value)
  • GF Score™: 50/100 with 2 warning signs

No single metric tells the full story. See the CHIX:MVIRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medivir AB Business Description

Address Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22
Medivir AB develops drugs with a focus on cancer, where unmet medical needs are high. The company is concentrating on the development of fostroxacitabine bralpamide (fostrox), a liver-targeted inhibitor of DNA replication that selectively delivers the cell-killing agent to the tumor while minimizing potentially harmful effects on normal cells. It has developed two pharmaceutical products: Xerclear, used for treating labial herpes (cold sores), and Olysio, which have reached the market. Medivir also also has four out-licensed projects Xerclear, MIV-701, MBLI/MET-X. Geographically, it generates its maximum revenue from Europe and other regions.
50GF Score

Get the complete analysis for CHIX:MVIRS

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr2.00
Price
kr1.24
GF Value